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IL-1 and IL-4 as reciprocal regulators of IL-2 induced lymphocyte
cytotoxicity
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Division of Surgical Oncology, Department of Surgery, 54-140 Center for Health Sciences, UCLA School of Medicine,
Los Angeles, CA 90024-1782, USA.
Summary Interleukin 4 (IL-4) suppresses the interleukin 2 (IL-2) induced lymphokine-activated killer (LAK)
cell development from human peripheral blood mononuclear cells (PBMC). Suppression is observed at high
(1,000 U ml-') as well as low (10 U ml-') concentrations of IL-2. IL-4 needs to be present at the beginning of
the IL-2 culture to exert the suppressive effect. IL-4 also inhibits the development of CD25 (Tac) antigen on
the PBMC cultured in IL-2. Interleukin I (IL-1) can reverse the suppressive effect of IL-4 on LAK induction
when added at the early phase of the IL-2 culture. IL-I enhances IL-2 induced LAK development, which may
partially explain the reversion of IL-4 inhibition by IL-1. IL-1 also reverses the inhibitory effect of IL-4 on the
development of CD25 antigen expression, although IL-1 alone does not enhance the induction of CD25
expression in PBMC cultured by IL-2. Furthermore, IL-4 suppresses IL-2 induced IL-1 production in PBMC.
Thus, suppression of CD25 may be a pathway for the suppression of LAK induction. The expression of CD56
is not directly associated with the expression of LAK activity. IL-4, IL-1 or combination of the two cytokines
has no effect on IL-2 induced expression of CD56. These results indicate that IL-4 has an antagonistic effect
and IL-1 has a synergistic effect on IL-2-induced LAK development.
Interleukin 4 (IL-4) has pleiotropic regulatory effects on com-
ponents of immune system including resting B cells, macro-
phages, mast cells, thymocytes (Gause et al., 1988) and
peripheral T cells (Brown et al., 1988; Kern et al., 1988).
Murine IL-4 can induce lymphokine activated killer (LAK)
function (Mule et al., 1987; Peace et al., 1988) and also acts
synergistically with interleukin 2 (IL-2) in LAK development
(Mule et al., 1989). With human cells, IL-4 suppresses IL-2
induced LAK development (Widmer et al., 1987; Spits et al.,
1988) even though IL-4 augments mixed lymphocytes culture
(MLC) induced development of antigen-specific cytotoxic T
lymphocytes (CTL) (Spits et al., 1988), influenza virus spe-
cific CTL induction (Horohov et al., 1988) and growth of
human tumour-infiltrating lymphocytes by IL-2 (Kawakami
et al., 1988).
Recently, it has been shown that IL-4 inhibits the secretion
of interleukin 1 (IL-1) from macrophages (Essner et al.,
1989), and IL-1 has been reported to promote IL-2 depend-
ent LAK development (Crump et al., 1989). Therefore, we
sought to define the manner in which IL-4 can suppress IL-2
induced LAK induction, and to determine if IL-1 can reverse
the IL-4 mediated suppression of LAK induction. To ap-
proach these questions, we examined the effect these cytokines
on modulation of cytotoxicity and on the expression of IL-2
activation markers such as CD25 (Tac) and CD56 (NKH1).
Materials and methods
Cell preparation and tymphocyte culture
Human peripheral blood mononuclear cells (PBMC) from
healthy volunteers were prepared by centrifugation on Ficoll-
Hypaque (Ficoll-Paque, Pharmacia, Piscataway, NJ, USA)
density gradients. PBMC were washed three times and re-
suspended in RPMI 1640 medium (Flow Laboratories, Mac-
Lean, VA, USA) containing antibiotics (GIBCO, Grand
Island, NY, USA) HEPES and 10% heat inactivated human
AB serum (Flow Laboratories, MacLean, VA, USA) in the
presence or absence of human recombinant ala-125 IL-2
analogue (AMgen Inc., Thousand Oaks, CA, USA), human
recombinant IL-4 (Immunex, Seattle, WA, USA) or human
recombinant IL-I beta (Immunex). The specific activities of
IL-2 and IL-4 are 2 x 106 units per mg of protein and 108
units per mg of protein respectively. Cells were cultured in
17 x 100 mm snap capped tubes (Falcon, Lincoln Park, NJ,
USA) for 4 days in a 5% CO2, 95% air atmosphere at 37°C.
Cytotoxicity assay
The NK-resistent LAK sensitive human melanoma cell line
UCLA-SO-M 14 (henceforth termed M 14) were maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum
(Flow Laboratories). M14 were treated briefly with 0.25%
trypsin solution to obtain a single cell suspension of the cells.
Cytotoxicity assays were performed in RPMI 1640 medium
supplemented with 10% human AB serum. Target cells were
labelled with 100 sCi of sodium 5"Cr-chromate (Amersham
International, Arlington Heights, IL, USA) for 60 min at
37°C and washed three times before use.
Cytotoxicity was tested in U-bottomed 96-well plate wells
(Dynatech Laboratories, Alexandria, VA, USA) with 200 1il
of assay medium containing 2.5 x 103 target cells and various
numbers of effector cells. The assays were initiated by low
speed centrifugation (50g for 4 min) followed by incubation
at 370C for 4 h. At the end of the incubation, 100 ;d of
supernatant was collected from each well for counting the
amount of chromium released. Cytotoxicity was determined by
the formula:
cytotoxicity = experimental release -spontaneous release
maximum release - spontaneous release x 100
Spontaneous release was determined from wells containing
no effector cells and total release was obtained from wells
containing target cells lysed by 5% NP40 detergent. Each
assay was done in triplicate. Each experiment was performed
with four different effector cell/target cell ratios (E/T ratios).
The per cent lysis of four E/T ratios within each experiment
were used to obtain a target cell survival curve and to
calculate lytic units (LU) by exponential fit (Pross et al.,
1981). A LU is defined as the number of effector cells
required to cause 30% lysis of target cells, and the results are
expressed as number of LU per 106 effector cells ± s.d.
Monoclonal antibodies (MoAb), surface marker determination
and IL-I determination
MoAb IL-2R-FITC (fluorescein isothiocyanate conjugated)
specific for CD25 (Tac) and MoAb NKH1-RD (phycoerith-
Correspondence: S.H. Golub.
Received 24 July 1989; and in revised form 8 May 1990.
19" Macmillan Press 1990Br. J. Cancer (1990), 62, 619-623
620 N. EBINA et al.
rin conjugated) specific for CD56 were obtained fron, Coul-
ter Immunology (Hialeah, FL, USA). Cells were incubated
with both antibodies for 30 min at 4°C, then washed three
times with PBS containing 2% normal bovine albumin and
0.02% sodium azide. The proportion of cells reacting with
MoAb was determined by two colour flow cytometric
analysis with a EPIC IV flow cytometer (Coulter).
IL-I concentrations of supernatants from IL-2 and/or IL-4
cultures were determined by EIA with an assay kit following
the manufacture's instruction (Cistron, Pine Brook, NJ,
USA). Each assay was done in duplicate.
Results
Effects of IL-4 on the induction ofLAK activity
To examine the effect of IL-4 on the induction on LAK
activity, PBMC were cultured with 50 U ml1' of IL-2 for 4
days in the presence of various concentrations of IL-4.
Cytotoxicity was measured against M 14 targets and the
results of two experiments are shown in Table I. Although
there is variation from one experiment to another in the
degree of suppression mediated by a given concentration of
IL-4, IL-4 from 10 to 100 U ml-' inhibited LAK induction in
a dose dependent manner. We chose 50 U ml-' of IL-4 as the
standard concentration that would give substantial suppres-
sion. LAK induction appears to be more sensitive to IL-4
regulation at low dose of IL-2, but 50 U ml-' of IL-4 is
suppressive to LAK development over a wide range of IL-2
concentrations up to 1,000 U ml-' (Figure 1). Based on these
results, we used 50 U ml-' as our standard IL-2 concentra-
tion.
In order to determine when IL-4 acts on LAK induction,
50 U ml-' of IL-4 was serially added to replicate 4 day
cultures of PBMC and IL-2 (Figure 2). The inhibitory effect
was observed only when IL-4 was added at the initiation of
LAK induction. When IL-4 was added 24 h or more after
IL-2, no significant inhibition was observed.
Table I Inhibitory effect of IL4 on LAK inductiona
IL-4 (U ml')
0 10 25 50 100
Exp. I
LU/10cellsb 198±27 54± 11 NT 13±6 12±4
% suppression 73 NT 93 93
Exp.2
LU/106cells 226±23 165± 18 127±21 65± 7 NT
% suppression 20 44 71 NT
'PBMC were incubated for 4 days with 50 U ml-' of rIL-2 in the
absence or presence of various amount of rIL-4. 'Values of cytotoxicity
are expressed in LU per 106 cells s.d.
200 - IL-2
1 10 50: 100 .500 1000
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Figure I Effect of IL-4 on the IL-2-induced LAK development.
PBMC were incubated for 4 days with various amount of IL-1 in
the absence or presence of IL-4 (50 U ml- '). Cytotoxicity was
assayed against M 14 targets, and values represent LU per 10o6
cells ± s.d.
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Figure 2 Effect of IL-4 serially added to replicate 4 day IL-2
cultures on generation of LAK activity. IL-4 (50 U ml-') was
serially added to PBMC cultures containing 50 U ml of IL-2.
The values of cytotoxicity tested on day 4 were expressed in LU
per 106 cells ± s.d.
Effect of IL-4 on CD25 and CD56 expression on PBMC
cultured with IL-2
IL-2 also induces expression of phenotypic markers including
CD25 (Siegel et al., 1987) and CD56 (Ramsdell et al., 1988).
Therefore, we examined the effect of IL-4 on the expression
of these two activation markers to determine whether IL-4
can influence these IL-2 induced changes. PBMC were in-
cubated with 50 U ml-1 of IL-2 in the absence or presence of
50 U ml-' of IL-4. Aliquots were harvested on day 4 of
culture, stained with monoclonal antibodies, and analysed by
flow cytometry. Results of three experiments are shown in
Table II. Our data show that IL-4 suppresses the IL-2
induced expression of CD25. These data also show that IL-4
has no effect on the total proportion of cells staining with
anti-CD56, while the intensity of both CD56 and CD25
staining is reduced by IL-4.
Antagonistic effect of IL-I on IL-4 mediated inhibition
IL-4 inhibits the secretion of interleukin 1 (IL-1) from mac-
rophages (Essner et al., 1989). Therefore, it is possible that
IL-4 inhibition of LAK is mediated through an effect on IL-1
production. To address this possibility, we assessed the effect
of IL-4 on IL-l-enhanced LAK development. We also inves-
tigated whether IL-1 can abrogate the IL-4 mediated sup-
pression of LAK development. PBMC were incubated with
50 U ml-' of IL-2 with or without 50 U ml-' of IL-4.
Various amounts of IL- I were added to the media at the
initiation of the culture. The results in Table III confirm
previous reports (Crump et al., 1989) that IL-1 can synergise
with IL-2 in activating LAK cells. IL-1 enhanced LAK
activity is sensitive to IL-4 suppression. Furthermore, IL-1
can partially abrogate the inhibitory effect of IL-4 in a dose
dependent manner.
IL-1 was added at different time points after the initiation
of LAK culture. The results are shown in Table IV. IL-1
augmented LAK activity as late as 72 h after the culture was
started and the addition of IL- 1 at 24 h showed optimal
enhancement of LAK activity. Again, the LAK activity
enhanced by IL-1 was suppressed by IL-4. It is of interest
that IL-4 is least suppressive at the time point when IL-1
shows optimal synergism with IL-2.
We also investigated the effect of IL-1 on CD25 and CD56
expression. Table V shows experiments where IL-1 partially
abrogated the suppression of CD25 expression by IL-4.
While IL-1 alone enhances the LAK induction of IL-2 cul-
tured PBMC as shown above, it does not synergise with IL-2
in inducing CD25 expression. Despite their regulatory effects
on LAK induction, neither IL-4 nor IL-1 modulates the
percentage of CD56+ cells in IL-2 culture. In experiment 1
(Table V), we examined the intensity of CD56 expression.
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Table II Effect of IL-4 on IL-2 induced CD25 and CD56 expression
Culture Treatment % CD25+ cells Mean channel % CD56+ cells Mean channel
Exp. I
IL-2 14 N.E. 8 N.E.
IL-2 + IL-4 8 N.E. 9 N.E.
Exp.2
IL-2 21 217 24 160
IL-2 + IL-4 14 122 26 94
Exp.3
IL-2 17 198 18 250
IL-2 + IL-4 15 W47 18 148
PBMC were incbated with 50 U ml' of rIL-2 with or without 50 U ml' of rIL-4. Aliquots were
harvested at the day 4 and then phenotypic analysis was performed. N.E., not examined.
Table III Effect of IL-1 on IL-4 mediated inhibition
IL-I (U ml-')
Culture Treatment 0 10 100 1000
Exp. I
IL-2 32.9 1.3 50.6 2.3 57.2 5.2 79.1 ± 4.6
IL-2 + IL-4 17.3 ± 2.1 20.8 ± 2.1 25.7 ± 2.2 37.5 ± 1.9
Exp.2
IL-2 96.2 12.3 111.8 9.6 176.2 25.1 190.4± 24.7
IL-2 + IL-4 35.4 9.6 41.7 4.3 114.1 ± 21.8 128.2 12.5
PBMC were incubated with 50 U ml-' of rIL-2 with or without 50 U ml- ' of rIL-4 in the
presence of various amount of rIL-1p. The values represent LU per 106 cells ± s.d.
Table IV Time course study of IL-I mediated abrogation of inhibition
IL-] added at (h)
Culture condition No IL-I 0 24 48 72
Exp. I
IL-2 122.4 ± 7.3 162.5 ± 2.4 210.7 ± 8.9 182.7 ± 8.2 165.6 ± 5.1
IL-2 + IL-4 13.4 ± 2.0 72.6 ± 7.3 90.0 ± 9.8 43.2 ± 7.0 28.0 ± 5.3
Exp.2
IL-2 40.2 2.8 55.3 ± 1.7 57.0 0.8 54.5 ± 1.9 51.3 ± 3.5
IL-2 + IL-4 12.1 ±4.3 27.1 ±2.2 22.8 1.33 18.1 ±3.4 16.6 ± 3.9
100 U ml-' of rIL-I3 was serially added to replicate 4 day cultures of PBMC and IL-2 (50 U ml-') with or
without rIL-4 (50 U ml-'). The values represent LU per 106 cells ± s.d.
Table V Effect of ILl on the expression of CD25 and CD56
% positive cells
Culture condition CD25 CD56
Exp. I
Medium only 6 9
IL-2 18 16
IL-2+IL-4 11 15
IL-2+IL-1 18 16
IL-2 + IL-4 + IL-1 14 14
Exp.2
IL-2 16 21
IL-2+IL-4 11 21
IL-2 + IL-1 16 22
IL-2+ IL-4+ IL-1 13 19
PBMC were incubated for 4 days in the medium containing various
mixtures of lymphokines indicated above, then aliquots were harvested
and phenotypic analyses were performed. The final concentration of
each cytokine used in the cultures was 50 U ml '.
PBMC incubated with IL-2 stained with anti-CD56 antibody
at a peak channel at 27. While IL-1 alone increases (peak
channel at 40) and IL-4 reduces (peak channel at 24) the
intensity of CD56 expression, IL-1 does not abrogate the
IL-4 mediated suppression of CD56 intensity (peak channel
at 21).
We have also tested the effect of IL-4 on IL-2 induced IL-1
production. PBMC were cultured in IL-2 for 4 days and the
cells were tested for LAK activity while their culture super-
natants were tested for IL-1-beta. Results from Table VI
show that IL-4 not only suppresses LAK cytotoxicity but
also significantly decreases IL-2 induced IL-1 production.
Table VI Effect of IL-4 on IL-2 induced LAK
production
Treatment
(u ml- ')
Control
IL-2 (100)
IL-2 (100) + IL-4 (50)
IL-2 (1000)
IL-2 (1000) + IL-4 (50)
LAK cytotoxicity
(LU ± s.d.)
0
252 ± 57
102 ± 8
258 ± 58
117± 16
activity and IL-1
IL-I production
(pg ml ')
193 ± 20
690 ± 22
123 ± 8
> 1000
389± 18
PBMC were cultured with indicated cytokines for 4 days; the cultured
cells were tested for LAK cytotoxicity against M 14 and the culture
supernatants were tested for IL-1 concentration by EIA.
Discussion
IL-4 inhibits the IL-2 induced LAK development of human
PBMC (Widmer et al., 1987; Spits et al., 1988). Our data not
only support these previous reports, but also show that
suppression of LAK is dependent on the dose of IL-4 (Table
I), and the suppression is effective over wide range of IL-2
concentration (10- 1,000 U ml-') (Figure 1).
IL-4 added more than 24 h after the initiation of IL-2
culture does not suppress LAK induction (Figure 2). Simi-
larly, other irvestigators have reported that IL-4 suppresses
LAK development only at the initiation of the IL-2 culture
(Spits et al., 1988). IL-4 has also been reported to inhibit the
activation of NK cells induced by short-term (18 h) incuba-
tion with IL-2 without any involvement of regulatory cells
(Nagler et al., 1988). This is in marked contrast to the effect
of IL-4 in enhancing MLC induced CTL induction or
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influenza virus specific CTL induction. These effects are more
profound if IL-4 is added at the later phase of incubation
(Horohov et al., 1988; Widmer et al., 1987). The differences
between CTL and LAK not only suggest that IL-4 has
different effects on different cytotoxic cells, but also indicate
that the effects of IL-4 depend on the different developmental
stage of the cytotoxic cells. With NK/LAK cells, IL-4
appears to act on an early phase in development of aug-
mented cytotoxicity.
One candidate for an early event sensitive to IL-4 suppres-
sion would be the induction of IL-2 receptors (CD25).
Therefore, we tested the effects of IL-4 on CD25 and CD56
expression. IL-4 suppresses the IL-2 induced expression of
CD25 but not CD56 (Table II). These data confirmed the
report of Brooks and Rees (1988) that IL-4 suppresses the
IL-2 induced expression of CD25 in both percentage of
positive cells and intensity of staining. In contrast, our results
indicate that the IL-4 does not suppress the percentage of IL-2
induced CD56 expressing cells, but does reduce the intensity of
CD56 expression. This suggests that inhibition of CD56 or
CD25 expression may be a mechanism by which IL-4 inhibits
LAK activity.
An alternative early event that might be affected by IL-4
might be IL-I production. Recently, it has been shown that
IL-4 inhibits the secretion of interleukin 1 (IL-1) from macro-
phages (Essner et al., 1989). This suggests that IL-4 mediated
inhibition on LAK induction may be through the suppres-
sion of IL-1 production triggered by IL-2. As shown in the
Tables III-V, IL-1 and IL-4 have antagonistic effects on
some IL-2 induced PBMC responses. IL-1 promotes LAK
development in a dose-dependent manner, while IL-4 sup-
presses this function (Table III). Synergism in LAK develop-
ment by IL-1 is most effective 2 days after initiation of the
culture and IL-4 is most suppressive when present from the
beginning of the culture (Table IV). In other words, IL-4 is
least suppressive at the point when IL-1 shows its most
significant enhancement of LAK development. More import-
antly our data directly show that IL-4 can suppress IL-2
induced IL-1 production in PBMC (Table VI). These results
strongly suggest that IL-4 mediated suppression of IL-1 pro-
duction may contribute to the inhibition of LAK induction.
We postulated that CD25 modulates the late phase of
LAK development but is not involved in the early phase of
LAK induction (Shau & Golub, 1985). Differences in timing
might explain the apparently divergent results with anti-
CD25 antibodies which have been found to have either no
effect on LAK induction (Tsudo et al., 1987) or to cause a
partial blocking of LAK induction (Grimm et al., 1983; Shau
et al., 1988). While the inhibition of LAK cytotoxicity by
anti-CD25 is often marginal and much less pronounced than
the inhibition of IL-2 induced lymphocyte proliferation (Sie-
gel et al., 1987), the combination of anti-CD25 and anti-
bodies specific for IL-2R-beta chain caused much greater
inhibition of LAK than the latter alone (Phillips et al., 1989).
This evidence suggests that CD25 does have some import-
ance in the generation of LAK function.
IL4 suppresses CD25 expression but the suppression can
be partially reversed by IL-1. This result, combined with the
fact that IL-1 can reciprocally regulate LAK function with
IL-4, indicates that suppression of CD25 expression and/or
reduced IL-1 production are likely to be involved in IL-4
suppression of LAK development. Neither cytokine alone or
in combination changes the percentage of CD56+ cells. How-
ever, IL-4 reduces and IL-1 enhances the intensity of CD56
expression individually. While IL-1 cannot reverse the IL-4
mediated suppression of CD56 intensity, it can partially
reverse the suppression of cytotoxicity. Therefore, these data
suggest that the expression of CD56 does not directly cor-
relate the development of LAK activity. Our results in this
study clearly indicate that IL-2 induced PBMC responses are
subject to regulation by other cytokines. IL-1 and IL-4 have
reciprocal effects of LAK development by IL-2, with IL-1
augmenting and IL-4 suppressing cytotoxicity.
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